latest update:
[TrialBase DB]

trial summary · NCT06882772

Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids

Butyric Acid Supplementation for Gut Improvement After Cardiac Surgery in Kids, A Phase IIa Clinical Trial

Trial record from the TrialBase DB dataset, status RECRUITING, condition Congenital Heart Disease (CHD), sponsored by University of Nebraska. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06882772phase PHASE1/PHASE2enrollment 105start 2026-11-01

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Butyric acid has been shown to promote gut health and improve the microbiome in multiple adult studies. In preliminary studies in older children with inflammatory bowel disease, butyric acid was shown to be safe. However, it's suitability for infants and young children with congenital heart disease (CHD) has yet to be determined. This study will examine butyric acid supplementation in infants and children, ages 1 month to 3 years, with CHD who require cardiac surgery with cardiopulmonary bypass. Study goals include determining the safety and tolerability of butyric acid supplementation before cardiac surgery, and to identify changes in gut microbial communities, metabolic profile, and genetic markers intestinal function. Also, the study seeks to establish a reduction in inflammation (inflammatory signaling) after cardiopulmonary bypass (CPB) in participants receiving butyric acid.

Source record: https://clinicaltrials.gov/study/NCT06882772

Facts

registry idNCT06882772
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionCongenital Heart Disease (CHD)
sponsorUniversity of Nebraska
sponsor classOTHER
enrollment105
start date2026-11-01
primary completion2029-06-30
completion2029-12-31
results postednot reported

Conditions

  • Congenital Heart Disease (CHD)

Interventions

  • 2 mL SunButyrate-TG
  • Placebo
  • 4 mL SunButyrate-TG

Countries

  • United States

Intervention types: DRUG

Work with this record